Home » NEXMED DEVELOPS ROOM TEMPERATURE FORMULATION OF ALPROX-TD FOR ERECTILE DYSFUNCTION
NEXMED DEVELOPS ROOM TEMPERATURE FORMULATION OF ALPROX-TD FOR ERECTILE DYSFUNCTION
NexMed, Inc., a developer of innovative treatments based on the NexACT technology, announced that it has confirmed the long term room temperature stability of Alprox-TD, the company's proprietary topical treatment for erectile dysfunction ("ED").
Market Wire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May